Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics Inc (NQ: TVTX )

18.26 +0.40 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 903,581
Open 17.96
Bid (Size) 18.25 (20)
Ask (Size) 18.26 (6)
Prev. Close 17.86
Today's Range 17.89 - 18.64
52wk Range 5.120 - 20.33
Shares Outstanding 60,717,176
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+91.00%
+91.00%
1 Month
+0.88%
+0.88%
3 Month
+110.13%
+110.13%
6 Month
+178.35%
+178.35%
1 Year
+223.19%
+223.19%

More News

Read More
3 Under-the-Radar Healthcare Companies
Via MarketBeat
A Preview Of Travere Therapeutics's Earnings
Via Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Via Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
Via Benzinga
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Travere Therapeutics Reports Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Via Benzinga
Travere Therapeutics to Report Third Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
Via Investor's Business Daily
Exposures Product Safety
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.